Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva’s multiple sclerosis drug tops comparative study
The US unit of Israeli drug maker Teva Pharmaceutical compared Copaxone to Betaferon, marketed by Chiron, Avonex, a Biogen Idec drug, and Serono’s Rebif treatment. Copaxone produced a
The US unit of Israeli drug maker Teva Pharmaceutical compared Copaxone to Betaferon, marketed by Chiron, Avonex, a Biogen Idec drug, and Serono’s Rebif treatment. Copaxone produced a
GTI-2501 has shown a favorable safety profile in preclinical studies and in a phase I clinical trial. The drug is currently in a phase II clinical trial, in
The ibandronic acid drug, known as Boniva in the US and Bonviva in Europe, proved to be as effective in a once monthly oral dose formulation as in
This phase II trial included 465 patients who were inadequately responding to methotrexate (MTX) treatment and who had failed prior treatment with one or more disease-modifying anti-rheumatic drugs.
Flow cytometry is a technology used in a family of diagnostic tests that combines hydrodynamics and a powerful light source, usually a laser, to isolate and analyze cells
The study will evaluate safety, tolerability and efficacy trends of G207 as well as potential synergies with radiation therapy. It is planned to enroll approximately 20 patients over
As a result of the option exercise, Vical, a specialist biopharmaceutical developer of DNA delivery technologies, will receive payments of $3 million, and further development may lead to
The company has enrolled 100 patients in a multi-center, randomized, double-masked, controlled, US phase II clinical trial with Evizon (squalamine lactate) for the treatment of choroidal neovascularization associated
The phase I study is a double-blind, randomized, placebo-controlled study that will enroll approximately 66 subjects with a single or multiple basal cell carcinoma. The study will be
Keflex is approved for treatment of respiratory tract infections caused by S. pneumoniae and S. pyogenes; otitis media due to S. pneumoniae, H. influenzae, and M. catarrhalis; and